| Característica |
Objectiu de la convocatòria
Funding for innovative projects in the field of non-alcoholic steatohepatitis (NASH).
|
Característiques principals
The ASPIRE NASH program will evaluate submitted research proposals that
cover areas in basic, clinical and translational sciences. The research
proposals with innovative and the potential of high impact in advancing the
learning about NASH will be encouraged.
The followings are the main areas of priority with high unmet needs:
Biopsy-confirmed NASH prevalence, clinical outcomes, and
healthcare utilization
Innovations in the use of non-invasive tools in the care of patients
with NASH
Understanding genetic drivers of NASH and identification of fast
progressors
Out of scope research includes:
Studies involving investigational products
Studies comparing a competitor drug vs. a Pfizer product
Highly invasive studies and studies that may have an ethical concern
Mere replication of existing studies (i.e., lack of innovation)
|
Lloc de presentació
IMIM and PSMAR staff who need more information should contact::
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
Marta López: mlopez4@imim.es Ext.: 1576
|
Convocatòria (URL)
https://cdn.pfizer.com/pfizercom/2023-09/2023-2024%20NASH%20ASPIRE%20RFP.pdf?T5cE4vA4fRjg0UR81OfcIGNI_GGgmrs_=
|
Requisits
Only organizations are eligible to receive grants, not individuals or medical practice groups.
If the project involves multiple departments within an institution and/or between different institutions /
organizations / associations. All institutions must have a relevant role and the requesting organization
must have a key role in the project.
The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing
degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research
coordinator).
The PI must be an employee or independent contractor of the requesting organization.
Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We
strongly recommend that applicants confirm this with their organization or institution prior to
submitting an application. Grants awarded to organizations that are subsequently found to be unable
to accept funding directly from Pfizer Inc. may be subject to rescission.
Both early career and experienced investigators are encouraged to apply and consideration will be
given to all proposals meeting the selection criteria
|
Dotació
Individual projects requesting up to USD $140,000 will be
considered. Pfizer anticipates awarding up to 3 grants and a total
fund of USD $420,000.
|
Durada
2-3 years.
|
Documentació
Proposals should be submitted at: https://www.cybergrants.com/pfizer/loi
|
AVÍS IMPORTANT
Application submission deadline: January 4, 2024
Anticipated decision notification date: May 2024
Grants will be distributed following a fully executed agreement
and submission of Final Protocol, documentation of IRB/IEC
approval, regulatory approval (if applicable), exemption or waiver.
|